Breaking News
Eli Lilly and Company
About Eli Lilly and Company
Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: “Take what you find here and make it better and better.”
More than 140 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live.
When the COVID-19 pandemic shut down the world, Lilly teams jumped in to attack it with everything we could. After an extraordinary year of loss, sacrifice and progress, Lilly scientists and leaders reflect on our purpose and how it powered their urgency and passion to help.
Eli Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
May 8 2023
Eli Lilly and Company have announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study […]
Roche Announces Collaboration with Lilly to Enhance Early Diagnosis of Alzheimer's Disease
March 22 2023
Roche announced today that it has entered into a collaboration with Eli Lilly and Company […]
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
March 2 2023
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]
US FDA Accepts Supplemental New Drug Application for Jardiance® for Adults with Chronic Kidney Disease
January 20 2023
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) […]
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
December 16 2022
Sosei Group Corporation announces it has entered a drug discovery collaboration with Eli Lilly and […]
Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly
August 12 2022
Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, […]
DTx Leader Sidekick Enters Strategic Collaboration With Lilly to Support Patients With Breast Cancer
June 20 2022
International digital therapeutics (DTx) innovator, Sidekick Health (www.sidekickhealth.com), today announces an integrated digital therapeutics solution in conjunction […]
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
May 23 2022
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency’s […]
Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
April 12 2022
At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined […]
Innovent and Lilly Expand Strategic Partnership in Oncology
March 28 2022
Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes […]
US FDA Approves Jardiance ® (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
February 25 2022
The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg to […]
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules
January 18 2022
Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: […]
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
December 13 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics […]
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
August 17 2021
Eli Lilly and Company (NYSE: LLY) today announced executive leadership changes and the creation of neuroscience […]
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
July 29 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and […]
Lilly Announces Acquisition of Protomer Technologies
July 14 2021
Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies (“Protomer”), a private […]
Diogo Rau to Join Lilly as Senior Vice-president and Chief Information and Digital Officer
April 13 2021
Eli Lilly and Company announced today that Diogo Rau will join the company on May 17, 2021 as senior vice-president […]
Lilly, Vir, GSK Announce Positive Topline Data from Phase 2 BLAZE-4 Trial
March 30 2021
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced […]